Safety of Timothy Grass sublingual immunotherapy tablet in children: Pooled analyses of clinical trials
Safety of Timothy Grass sublingual immunotherapy tablet in children: Pooled analyses of clinical trials
Background: Timothy grass sublingual immunotherapy (SLIT) tablets are indicated for children with allergic rhinitis with or without conjunctivitis. Objective: To use pooled analyses to assess the short- and long-term tolerability and safety of timothy grass SLIT-tablet in children. Methods: Data from 9 double-blinded, randomized European or North American trials that included children with allergic rhinitis with or without conjunctivitis treated up to 3 years with once-daily timothy grass SLIT-tablet or placebo were pooled. Results: In all, 1818 (timothy grass SLIT-tablet, n = 923; placebo, n = 895) subjects were included in the analysis. The frequency of treatment-emergent adverse events (AEs) was 86% in the SLIT-tablet group and 83% in the placebo group, and the frequency of treatment-related AEs (TRAEs) was 59% and 23%, respectively. Most (98%) TRAEs were mild to moderate in severity. The 2 most common TRAEs with SLIT-tablet were oral pruritus (33%) and throat irritation (19%), which had a median onset of 1 day and recurrence of 14.5 and 5 days, respectively. In all, 8% of subjects in the SLIT-tablet group and 2% in the placebo group discontinued because of AEs. There were 7 serious AEs assessed as related to SLIT-tablet, 1 systemic allergic reaction (severe with a drop in blood pressure), 3 epinephrine administrations, no eosinophilic esophagitis events, and no serious airway obstructions. The safety profile was similar in subjects across geographic regions and with and without asthma. Conclusions: Pooled data indicate that short- and long-term timothy grass SLIT-tablet is well tolerated in children, regardless of geographic region. AEs were generally local, mild, and transient allergic reactions.
Allergic rhinitis, Children, Grass, Immunotherapy, Safety, Sublingual
1387-1393.e2
Halken, Susanne
2d3b1100-70d1-46e1-8466-15990d478a9f
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Valovirta, Erkka
ef88c572-ca23-4dce-8026-0b0e142ab024
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Hulstrom, Veronica
1414a93f-e6f0-4f23-b7fd-dd7027acdbf1
Blaiss, Michael S.
5bfffae8-a07d-4a12-bf0d-ba8553b7b837
April 2020
Halken, Susanne
2d3b1100-70d1-46e1-8466-15990d478a9f
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Valovirta, Erkka
ef88c572-ca23-4dce-8026-0b0e142ab024
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Hulstrom, Veronica
1414a93f-e6f0-4f23-b7fd-dd7027acdbf1
Blaiss, Michael S.
5bfffae8-a07d-4a12-bf0d-ba8553b7b837
Halken, Susanne, Roberts, Graham, Valovirta, Erkka, Nolte, Hendrik, Hulstrom, Veronica and Blaiss, Michael S.
(2020)
Safety of Timothy Grass sublingual immunotherapy tablet in children: Pooled analyses of clinical trials.
The Journal of Allergy and Clinical immunology: In Practice, 8 (4), .
(doi:10.1016/j.jaip.2020.01.008).
Abstract
Background: Timothy grass sublingual immunotherapy (SLIT) tablets are indicated for children with allergic rhinitis with or without conjunctivitis. Objective: To use pooled analyses to assess the short- and long-term tolerability and safety of timothy grass SLIT-tablet in children. Methods: Data from 9 double-blinded, randomized European or North American trials that included children with allergic rhinitis with or without conjunctivitis treated up to 3 years with once-daily timothy grass SLIT-tablet or placebo were pooled. Results: In all, 1818 (timothy grass SLIT-tablet, n = 923; placebo, n = 895) subjects were included in the analysis. The frequency of treatment-emergent adverse events (AEs) was 86% in the SLIT-tablet group and 83% in the placebo group, and the frequency of treatment-related AEs (TRAEs) was 59% and 23%, respectively. Most (98%) TRAEs were mild to moderate in severity. The 2 most common TRAEs with SLIT-tablet were oral pruritus (33%) and throat irritation (19%), which had a median onset of 1 day and recurrence of 14.5 and 5 days, respectively. In all, 8% of subjects in the SLIT-tablet group and 2% in the placebo group discontinued because of AEs. There were 7 serious AEs assessed as related to SLIT-tablet, 1 systemic allergic reaction (severe with a drop in blood pressure), 3 epinephrine administrations, no eosinophilic esophagitis events, and no serious airway obstructions. The safety profile was similar in subjects across geographic regions and with and without asthma. Conclusions: Pooled data indicate that short- and long-term timothy grass SLIT-tablet is well tolerated in children, regardless of geographic region. AEs were generally local, mild, and transient allergic reactions.
This record has no associated files available for download.
More information
Accepted/In Press date: 6 January 2020
e-pub ahead of print date: 15 January 2020
Published date: April 2020
Additional Information:
Funding Information:
We thank Erin P. Scott of Scott Medical Communications, LLC, for providing medical writing and editorial assistance. This assistance was funded by ALK-Abelló , Hørsholm, Denmark.
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
Keywords:
Allergic rhinitis, Children, Grass, Immunotherapy, Safety, Sublingual
Identifiers
Local EPrints ID: 440606
URI: http://eprints.soton.ac.uk/id/eprint/440606
ISSN: 2213-2198
PURE UUID: 5e173f1d-7272-476a-b355-1c5624c6b6df
Catalogue record
Date deposited: 12 May 2020 16:31
Last modified: 17 Mar 2024 03:01
Export record
Altmetrics
Contributors
Author:
Susanne Halken
Author:
Erkka Valovirta
Author:
Hendrik Nolte
Author:
Veronica Hulstrom
Author:
Michael S. Blaiss
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics